| Difference all patients | p-value | Difference treatment group 1 | Difference treatment group 2 | p-value | |
---|---|---|---|---|---|---|
N | Â | 23 | Â | 10 | 13 | Â |
CTx ng/L | Median (IQR) | 83 (2, 155) | <0.001 | 17 (−27, 83) | 131 (79, 171) | 0.034 |
BSAP IU/L | Median (IQR) | 1 (0, 4) | 0.011 | 0 (−1, 1) | 3 (2, 5) | 0.010 |
TGF-β, ng/ml | Median (IQR) | 0.8 (−2.1, 4.9) | 0.28 | −0.1 (−2.1, 2.2) | 2.4 (−0.0, 4.9) | 0.41 |
Activin-A, pg/ml | Median (IQR) | 111 (28, 526) | 0.001 | 96 (−29, 596) | 122 (34, 256) | 0.60 |
NTx 2nM BCE/mM creatine | Median (IQR) | 42 (−48, 168) | 0.15 | 42 (−15, 179) | 45 (−76, 108) | 0.54 |
P1NP ng/ml | Median (IQR) | 5742 (−6694, 19129) | 0.24 | 1376 (−6694, 8498) | 16539 (−1266, 21993) | 0.26 |
BSP ng/ml | Median (IQR) | 5.8 (−8.0, 9.5) | 0.63 | 0.5 (−15.4, 6.4) | 9.8 (0.8, 47.2) | 0.14 |
FACT -BP | Median (IQR) | 0 (−4, 3) | 0.99 | 1 (0, 4) | −2 (−4, 1) | 0.053 |
BPI | Median (IQR) | 0 (−3, 4) | 0.94 | 2 (0, 7) | −1 (−8, 1) | 0.050 |